Y Intercept Hong Kong Ltd Acquires 1,008,548 Shares of ADMA Biologics Inc $ADMA

Y Intercept Hong Kong Ltd grew its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 1,508.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,075,422 shares of the biotechnology company’s stock after buying an additional 1,008,548 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in ADMA Biologics were worth $9,690,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after acquiring an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP raised its holdings in ADMA Biologics by 27.0% during the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Capital Research Global Investors grew its stake in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC grew its stake in ADMA Biologics by 3.5% in the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after purchasing an additional 202,245 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Zacks Research downgraded ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Finally, Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.67.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $8.95 on Friday. The business’s 50 day moving average price is $8.70 and its two-hundred day moving average price is $13.01. The company has a market cap of $2.07 billion, a PE ratio of 13.16 and a beta of 0.73. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same quarter in the prior year, the company earned $0.11 earnings per share. The business’s revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts predict that ADMA Biologics Inc will post 0.82 EPS for the current year.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Bronstein, Schall, Glancy Prongay, Berger Montague, KSF, Faruqi & Faruqi, and Kirby McInerney, issued reminders about the ongoing ADMA Biologics securities class action and the approaching August 10 lead plaintiff deadline. Article: Rosen, National Investor Counsel, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ADMA
• Neutral Sentiment: The complaints allege violations of federal securities laws and claim investors who bought ADMA shares during the class period may have suffered losses, which keeps legal risk in focus. Article: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Neutral Sentiment: One filing specifically alleges ADMA made misrepresentations about its revenue sources, adding to concerns about the company’s prior disclosures. Article: ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 3.90% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.